Efficacy and safety of infliximab biosimilar Inflectra® in severe sarcoidosis

Autor: Frouke T. van Beek, Marcel Veltkamp, Milou C. Schimmelpennink, Adriane D.M. Vorselaars, Ruth G.M. Keijsers, Heleen A. Crommelin, Vera H.M. Deneer
Rok vydání: 2018
Předmět:
Zdroj: Respiratory Medicine. 138:S7-S13
ISSN: 0954-6111
DOI: 10.1016/j.rmed.2018.02.009
Popis: Background Infliximab, a monoclonal antibody against tumor necrosis factor alpha (TNF-α) is effective third-line therapy in severe sarcoidosis. The originator product of Infliximab, Remicade®, is expensive, limiting universal access. Recently, a less expensive biosimilar of infliximab, Inflectra®, has become available, but the efficacy and tolerability has not been studied in sarcoidosis. Methods In this retrospective cohort study, 29 patients treated with the infliximab biosimilar Inflectra®, were analysed. Patients received Inflectra® intravenously monthly at a dose of 5 mg/kg. We measured trough levels before every infusion. Before and after 6 months of induction therapy pulmonary function and disease activity were evaluated using Standardised Uptake Value (SUV) of the 18F-fluorodeoxyglucose by positron emission tomography (18F-FDG PET), soluble interleukin-2 receptor (sIL-2R), angiotensin converting enzyme (ACE) and health-related quality of life (HRQOL). Results In patients with pulmonary sarcoidosis as main treatment indication (n = 15) the predicted FVC improved with 8.1%, p Conclusion Infliximab biosimilar Inflectra® seems effective in the treatment of refractory sarcoidosis with a comparable safety profile to the reference product Remicade®. Inflectra® can be considered as an alternative and less expensive option for patients with refractory sarcoidosis.
Databáze: OpenAIRE
Externí odkaz: